GlassScriptPhysician profile
Khin M Kyi
NPI 1891717831
$327.13
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $86.85 · 2021: $97.97.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $97.97 | 2021 | |
| Scilex Pharmaceuticals INC. | $47.31 | 2019 | |
| Genzyme Corporation | $34.63 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.52 | 2019 | |
| Exelixis INC. | $19.01 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.17 | 2020 | |
| Incyte Corporation | $15.28 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.35 | 2019 | |
| Janssen Biotech, INC. | $13.00 | 2020 | |
| Lilly USA, LLC | $12.84 | 2019 | |
| Astellas Pharma US INC | $12.69 | 2020 | |
| Amgen INC. | $12.19 | 2020 | |
| Celgene Corporation | $12.17 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khin Kyi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.